ClinicalTrials.gg
CompletedNCT06680440Updated May 20, 2025

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

A Phase 1 interventional study of ASC30 and Placebo in Weight Management, sponsored by Ascletis Pharma (China) Co., Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Ascletis Pharma (China) Co., Limited (part of Ascletis Pharma Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.

02

Conditions studied

  • Weight Management
03

In context

Lead sponsor

Ascletis Pharma (China) Co., Limited is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have provided before initiation of any study-specific procedures.
  2. Male or female participants, non-smokers, between 18 and 65 years of age (both inclusive).
  3. No findings from medical history, physical examination, 12-lead , vital signs measurements, and other screening procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have evidence of any active or chronic disease.
  2. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or rare forms of diabetes mellitus.
  3. Have an disease, is or is in any way immunocompromised.
  4. Have a history of acute or chronic pancreatitis.
  5. Participants with a known clinically significant gastric emptying abnormality.
  6. Have a history of an active or untreated or are in remission from a clinically significant malignancy.
  7. Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the Investigator, may preclude the participant from following and completing the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    SAD Cohort 1

    SAD dose 1

    Drug: ASC30 · Other: Placebo

  • Experimental
    SAD Cohort 2

    SAD dose 2

    Drug: ASC30 · Other: Placebo

  • Experimental
    SAD Cohort 3

    SAD dose 3

    Drug: ASC30 · Other: Placebo

  • Experimental
    SAD Cohort 4

    SAD dose 4

    Drug: ASC30 · Other: Placebo

  • Experimental
    SAD Cohort 5

    SAD dose 5

    Drug: ASC30 · Other: Placebo

  • Experimental
    MAD Cohort 1

    MAD dose 1

    Drug: ASC30 · Other: Placebo

  • Experimental
    MAD Cohort 2

    MAD dose 2

    Drug: ASC30 · Other: Placebo

  • Experimental
    MAD Cohort 3

    MAD dose 3

    Drug: ASC30 · Other: Placebo

Interventions

  • DrugASC30

    Tablet, QD

  • OtherPlacebo

    Tablets, QD

06

What researchers measure

Primary outcomes

  1. Incidence of AEs, SAEs (Safety and Tolerability) of ASC30 (SAD)

    A summary of AEs, SAEs and other non-serious adverse events

    Time frame: Up to Day 8

  2. Incidence of AEs, SAEs (Safety and Tolerability) of ASC30 (MAD)

    A summary of AEs, SAEs and other non-serious adverse events

    Time frame: Up to Day 28

Secondary outcomes

  1. Cmax of ASC30 (SAD)

    PK parameters of ASC30

    Time frame: Up to Day 8

  2. Cmax of ASC30 (MAD)

    PK parameters of ASC30

    Time frame: Up to Day 28

  3. Change From Baseline in Body Weight (MAD)

    Change From Baseline in Body Weight

    Time frame: Up to Day 28

07

Study locations

1 site
  • Ascletis clinical site
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Apr 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Nov 8, 2024
StartActual
Aug 26, 2024
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 3, 2025
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06680440
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Aug 26, 2024
Primary completion
Apr 3, 2025
Completion
Apr 3, 2025
Last update
May 20, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ASC30

Start the discussion